This page follows insider dealings at RCM Technologies, Inc. as filed with SEC (Form 4), a company from the Industry sector. Between 18 October 2025 and 18 October 2026, 11 insiders published 43 filings.
Only sales appear on the open market, 29 sales in all totalling €10.2M, filed by 3 insiders. Biggest ticket of the year: €1.7M, sold by Vizi Bradley and made public on 18 August 2026 (0.68% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,814 companies, median 19 filings), a count of 43 filings is above the norm. Since 2021, the database holds no purchases and 77 sales by insiders of the company. The 10-K for the year ended 3 January 2026 shows 319.4 m USD of revenue and 16.3 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Tennant Co and Butler National Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 115 declarations
RCM Technologies, Inc. (Nasdaq: RCMT) is a U.S.-listed business services and technology solutions company traded on the American market within the NYSE/NASDAQ universe. Headquartered in Pennsauken, New Jersey, United States, the company traces its roots back to 1971. RCM is not a pure software vendor; rather, it is a diversified services provider that combines engineering expertise, specialized staffing, and transformation-oriented technology services for industrial, healthcare, and institutional clients.
Today, RCM Technologies is organized into three operating segments: Engineering; Specialty Health Care; and Life Sciences, Data & Solutions. The Engineering segment provides applied engineering, project execution, design support, and technical solutions for complex environments, with exposure to aerospace and defense, energy, critical infrastructure, and process and industrial markets. Specialty Health Care delivers healthcare staffing solutions, including nurses, therapists, medical professionals, health information management specialists, and other clinical talent, serving major healthcare institutions and school districts across the United States. Life Sciences, Data & Solutions focuses on business modernization, data-driven process improvement, and technology-enabled services for life sciences and other mission-critical end markets.
From a competitive standpoint, RCM operates in niches where sector depth, speed of delivery, and access to hard-to-find talent matter more than scale alone. Its mid-cap profile gives it more flexibility than a large systems integrator while still providing diversification across several end markets. The company has a primarily domestic footprint in the United States, but it also operates in Canada, Puerto Rico, Europe, Germany, and the Philippines. That said, the majority of revenue is generated in the United States.
Recent company communications in 2025 and 2026 indicate continued activity across project execution and the positioning of its engineering, specialty healthcare, and data solutions capabilities. For equity investors, RCM also attracts attention through SEC Form 4 insider transaction filings, which show recurring activity at the management and controlling-shareholder level. Overall, RCM Technologies remains a diversified small-cap services name with long operating history, a broad but focused service portfolio, and meaningful exposure to staffing and project-based demand cycles.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Jan 2026 | 319.4 m USD | 16.3 m USD | 2.14 USD | 10-K |
| Dec 2024 | 278.4 m USD | 13.3 m USD | 1.68 USD | 10-K |
| Dec 2023 | 263.2 m USD | 16.8 m USD | 1.96 USD | 10-K/A |
| Dec 2022 | 284.7 m USD | 20.9 m USD | 2.00 USD | 10-K |
| Jan 2022 | 203.9 m USD | 11.0 m USD | 0.95 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.